ClinicalTrials.gg
Not yet recruitingNCT07944430OPTIMAL-DOSEUpdated Nov 18, 2026

Clinician-Selected FSH Starting Dose and Mature Oocyte Yield in Predicted Poor Responders

An observational study in Infertility, Female, Poor Ovarian Response and Diminished Ovarian Reserve, sponsored by American Hospital 2 Kosovo. Not yet recruiting at 1 site in Kosovo. Open to female participants aged 18 Years to 42 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by American Hospital 2 Kosovo · Observational

How we know

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
160
Ages
18 Years to 42 Years
Sex
Female
01

Study summary

This is a single-centre, prospective, non-interventional (observational) cohort study examining the association between the clinician-selected starting dose of follicle-stimulating hormone (FSH) and the yield of mature metaphase II (MII) oocytes in women with predicted poor ovarian response (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number [POSEIDON] group 3 or 4) undergoing in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) with a gonadotropin-releasing hormone (GnRH) antagonist protocol. The FSH dose is chosen by the treating physician as part of routine care; the study does not allocate, randomize, or change treatment. The primary outcome is the number of MII oocytes per initiated index cycle. Because dosing is not randomized, analyses are adjusted for measured confounders and address confounding by indication.

Read the detailed description

Randomized evidence in predicted poor responders (a randomized trial in predicted poor responders and the 2024 Cochrane review of individualised gonadotropin dosing) does not show improved live birth from higher follicle-stimulating hormone (FSH) dosing, so this cohort is not designed to establish comparative efficacy; its contribution is a description of real-world dose-response patterns and local gonadotropin use and cost. Consecutive eligible women are enrolled after informed consent for data use, each contributing one index cycle. The exposure is the clinician-selected starting FSH dose, analysed as a continuous variable (per 75 international units [IU]), with categories of 150 IU or less versus more than 150 IU reported descriptively and in sensitivity analyses. The primary analysis is an adjusted negative-binomial regression of the metaphase II (MII) oocyte count on exposure, with adjusted means obtained by marginal standardization and an overlap-weighted propensity analysis as sensitivity. Reporting follows the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) and REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statements.

02

Conditions studied

  • Infertility, Female
  • Poor Ovarian Response
  • Diminished Ovarian Reserve

Browse trials for

03

In context

Infertility, Female

553 studies on the registry are indexed under Infertility, Female; 134 are open to participants now.

This study's planned enrollment of 160 is close to the median of 160 across 163 observational studies indexed under Infertility, Female.

Browse Infertility, Female studies →

Lead sponsor

American Hospital 2 Kosovo is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 42 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Consecutive women aged 18 to 42 years with predicted poor ovarian response (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number (POSEIDON) group 3 or 4: anti-Mullerian hormone below 1.2 ng/mL and/or antral follicle count below 5) undergoing a gonadotropin-releasing hormone (GnRH) antagonist in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle as part of routine clinical care at American Hospital Kosova, each contributing one index cycle.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Woman aged 18 to 42 years.
  2. Predicted poor ovarian response, Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number (POSEIDON) group 3 (under 35 years) or group 4 (35 years or older): anti-Mullerian hormone (AMH) below 1.2 ng/mL and/or antral follicle count (AFC) below 5 (both ovaries combined).
  3. Planned gonadotropin-releasing hormone (GnRH) antagonist in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle as part of routine clinical care.
  4. First eligible (index) cycle during the study period; both ovaries present.
  5. Written for data collection and processing.

Exclusion criteria

Exclusion Criteria:

  1. Predicted normal or high ovarian reserve (AMH 1.2 ng/mL or higher and AFC 5 or higher).
  2. Non-antagonist protocol (for example, long GnRH-agonist).
  3. Oocyte-donation or fertility-preservation (egg-freezing) cycle.
  4. A prior cycle of the same woman already enrolled in the study.
  5. Inability to provide .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
160 participants (estimated)
Patient registry
No

Groups and cohorts

  • Lower starting dose (150 international units [IU] or less)

    Women whose treating physician chose a starting daily follicle-stimulating hormone (FSH) dose of 150 international units (IU) or less as part of routine clinical care (observed, not assigned by the study).

    Drug: Follicle-stimulating hormone (FSH)

  • Higher starting dose (more than 150 IU)

    Women whose treating physician chose a starting daily FSH dose of more than 150 IU (typically 225 IU) as part of routine clinical care (observed, not assigned by the study).

    Drug: Follicle-stimulating hormone (FSH)

Interventions

  • DrugFollicle Stimulating HormoneStudies of Follicle Stimulating HormoneFollicle Stimulating Hormone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    FSH administered per routine clinical practice; the starting dose is selected by the treating physician (observed exposure, not assigned by the study). Starting dose is analysed continuously (per 75 IU), with categories of 150 IU or less versus more than 150 IU reported descriptively.

06

What researchers measure

Primary outcomes

  1. Number of mature metaphase II (MII) oocytes retrieved

    Number of metaphase II (MII) oocytes retrieved per initiated index ovarian stimulation cycle, assessed by the embryologist at a standardized time after oocyte retrieval. Compared across the clinician-selected starting-dose exposure using adjusted analysis (associations, not causal effects). Cycles cancelled before oocyte retrieval contribute zero MII oocytes in the initiated-cycle analysis. Oocytes matured in vitro are excluded from the primary count.

    Time frame: On the day of oocyte retrieval (up to 21 days after the start of ovarian stimulation)

Secondary outcomes

  1. Total follicle-stimulating hormone (FSH) activity administered

    Total follicle-stimulating hormone (FSH) activity administered during the index stimulation cycle, in international units (IU), by observed starting-dose exposure. FSH activity is recorded separately from luteinizing hormone (LH) and human chorionic gonadotropin (hCG) activity.

    Time frame: From the first to the last day of ovarian stimulation (up to 21 days)

  2. Gonadotropin medication cost

    Cost of the gonadotropin medication used during the stimulation cycle, in euros (EUR), calculated using a pre-specified standardized unit-price table, by observed starting-dose exposure.

    Time frame: From the first to the last day of ovarian stimulation (up to 21 days)

  3. Total number of oocytes retrieved

    Total number of oocytes retrieved at oocyte pick-up per initiated index cycle, by observed starting-dose exposure.

    Time frame: On the day of oocyte retrieval (up to 21 days after the start of ovarian stimulation)

  4. Oocyte maturity rate

    Ratio of the number of metaphase II (MII) oocytes to the total number of oocytes retrieved in the index cycle, by observed starting-dose exposure.

    Time frame: On the day of oocyte retrieval (up to 21 days after the start of ovarian stimulation)

  5. Cycle cancellation before oocyte retrieval

    Whether the initiated index cycle was cancelled before oocyte retrieval, by observed starting-dose exposure.

    Time frame: From the first day of ovarian stimulation to the planned day of oocyte retrieval (up to 21 days)

  6. Duration of ovarian stimulation

    Number of days of ovarian stimulation during the index cycle, by observed starting-dose exposure.

    Time frame: From the first to the last day of ovarian stimulation (up to 21 days)

  7. Number of normally fertilised oocytes with two pronuclei (2PN)

    Number of oocytes showing two pronuclei (2PN) at the fertilisation check in the index cycle, by observed starting-dose exposure.

    Time frame: At the fertilisation check, 1 day after oocyte retrieval (up to 22 days after the start of ovarian stimulation)

  8. Number of usable embryos

    Number of embryos from the index cycle that are transferred, cryopreserved or biopsied, meeting the minimum grade of the pre-specified laboratory standard, by observed starting-dose exposure. Each embryo is counted once.

    Time frame: Up to 6 days after oocyte retrieval (up to 27 days after the start of ovarian stimulation)

  9. Number of blastocysts

    Number of embryos from the index cycle reaching the blastocyst stage, by observed starting-dose exposure.

    Time frame: Up to 6 days after oocyte retrieval (up to 27 days after the start of ovarian stimulation)

Other outcomes

  1. Live birth (exploratory)

    Delivery of at least one live-born infant, recorded per initiated index cycle and per transfer. Exploratory only; the study is not powered for this outcome and it is highly susceptible to confounding by indication. Reported descriptively.

    Time frame: Up to 12 months after the start of ovarian stimulation

  2. Clinical pregnancy (exploratory)

    Presence of an intrauterine gestational sac on ultrasound after the first fresh or frozen embryo transfer from the index cycle, recorded per initiated index cycle and per transfer. Exploratory only; the study is not powered for this outcome. Reported descriptively.

    Time frame: At 7 weeks of gestation (approximately 5 weeks after the first embryo transfer)

07

Study locations

1 site
  • American Hospital Kosova
    Pristina, 10000, Kosovo
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Oct 2028, 23 months later.

Of 85 non-industry observational studies under Infertility, Female, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 69. This study's planned 23 months is below that.

Counting every sponsor, half of 88 studies reached it within 36 months; a quarter within 18 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 18, 2026
StartEst.
Nov 2026
Primary completionEst.
Oct 2028
CompletionEst.
Aug 2029
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07944430
Lead sponsor
American Hospital 2 Kosovo
Responsible party
Goksu Goc (Principal Investigator, American Hospital 2 Kosovo) — Principal investigator
First posted
Nov 18, 2026
Start date
Nov 2026 (estimated)
Primary completion
Oct 2028 (estimated)
Completion
Aug 2029 (estimated)
Last update
Nov 18, 2026

Study contacts

Goksu Goc, MD
Contact
goksu.goc@gmail.com
+383 49 878 550

Oversight

FDA-regulated drug
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion